ArticleInterdisciplinary sciences, computational life sciences2026
DiM2-DRP: Dual-Input Multi-View Dynamic Contrastive Learning Framework for Drug Response Prediction.
Article in Interdisciplinary sciences, computational life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Accurately modeling cellular states is crucial for pharmacogenomics, yet existing deep learning methods often rely on shallow representations that fail to capture complex drug-cell interactions. These limitations necessitate a multi-view architecture that synergistically leverages multiple biological modalities to explicitly capture drug-cell interactions. Here, we propose DiM2-DRP, a dual-input multi-view framework that integrates heterogeneous and complementary views from cancer cells and small-molecule compounds. The framework develops a network-informed cell encoder that integrates bi-directional network diffusion with stability-guided pathway clustering to derive compact, biologically consistent representations. A novel bi-directional attention-based contrastive fusion module integrates these cellular representations with drug features extracted by a structure-informed drug encoder, dynamically adjusting cross-modal alignment according to interaction strength. By emphasizing biologically relevant drug-cell dependencies, this architecture alleviates the shallow integration limitations of conventional methods. Furthermore, an auxiliary classification module imposes lineage-specific and target-pathway constraints, ensuring the learned representations are both mechanistically grounded and robust for drug response prediction. Experiments show that DiM2-DRP achieves higher predictive accuracy, improved drug-blind and cell-blind generalization, and enhanced biological interpretability compared with existing methods. The pathway signatures recovered by the model remain consistent in patient tumours and are associated with multiple clinical outcomes, supporting the translational relevance of the learned representations. By leveraging a multimodal architecture integrated with dynamic contrastive learning, DiM2-DRP refines the characterization of drug sensitivity, offering a robust framework to support precision oncology strategies.
Indexed as
Identifiers
42778845What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.